Transforming obesity medicine with artificial intelligence: personalization, precision and the path ahead - Top-Institutions - MDSpire

Transforming obesity medicine with artificial intelligence: personalization, precision and the path ahead

  • By

  • Rajiev K Hallock

  • Marcio L Griebeler

  • Bartolome Burguera

  • Peminda Cabandugama

  • January 5, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Obesity Medicine
    • Artificial Intelligence
    • Precision Medicine
    • Digital Health

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Obesity Medicine
    • Artificial Intelligence
    • Digital Health
    • Behavioral Science

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Obesity Medicine
    • Artificial Intelligence
    • Metabolic Research
    • Digital Health

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Obesity Medicine
    • Artificial Intelligence
    • Precision Medicine
    • Digital Health

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Obesity Medicine
    • Artificial Intelligence
    • Digital Health
    • Behavioral Science

Original Source(s)

Transforming obesity medicine with artificial intelligence: personalization, precision and the path ahead

  • by Rajiev K Hallock, Marcio L Griebeler, Bartolome Burguera, Peminda Cabandugama

  • January 5, 2026

Related Content

Pasteurized Akkermansia muciniphila alleviates high-fat diet-induced bone loss via Nr4a1-dependent Treg differentiation

The relationships between fat-soluble vitamin deficiency and childhood obesity risk

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.